LDL-C goal attainment was achieved by only 23.4% of patients in the France cohort, compared to 31.6% in the rest of Europe cohort, indicating continued suboptimal lipid management in high cardiovascular risk patients in France.
Observational (n=621)
Yes
Does routine lipid-lowering therapy management improve LDL-C goal attainment in high and very high cardiovascular risk patients in France compared to the rest of Europe?
Despite increases in combination lipid-lowering therapy over 1 year, the vast majority of high-risk patients in France and Europe fail to achieve guideline-recommended LDL-C goals.
Absolute Event Rate: 23.4% vs 31.6%
Background The SANTORINI study (NCT04271280) was designed to assess lipid management in different European countries and care settings over 1 year of follow-up. Here, we report prospective findings of patient characteristics, low-density lipoprotein cholesterol (LDL-C) goal attainment, and treatment patterns of lipid-lowering therapies (LLTs) in France and the rest of Europe (RoE; without France) at 1-year follow-up. Materials and methods Patients at high or very high cardiovascular (CV) risk were recruited across 14 European countries from 17 March 2020 to 11 February 2021 and followed for 1 year of prospective follow-up. Results Among 9,559 patients enrolled in the study, 8,802 with available risk classification data and 7,210 with available LDL-C data at baseline and 1-year follow-up were included. Of patients with available LDL-C data, 621 were included in the France cohort and 6,589 were included in the RoE cohort. In the France cohort (full analysis set for risk), investigators classified 20.1% and 79.9% of patients as high and very high CV risk, respectively. When CV risk was recalculated centrally as per the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines, 7.1% and 92.9% of patients in the France cohort were considered high and very high risk, respectively. Total LLT monotherapy and combination therapy use over 1 year increased from 51.2% to 58.5% and 25.3% to 38.2%, respectively. Overall, mean (standard deviation) LDL-C level decreased from 2.6 (1.3) mmol/L to 2.2 (1.2) mmol/L, and LDL-C goal attainment increased from 14.8% to 23.4%. Results in the France cohort were consistent with those observed in the RoE cohort. Conclusions While use of combination LLT and LDL-C goal attainment increased in the France cohort over 1 year of follow-up, the majority of patients remained at an increased risk of CV events.
Ferrières et al. (Thu,) conducted a observational in High and very high cardiovascular risk (n=621). Lipid-lowering therapies vs. Rest of Europe cohort was evaluated on LDL-C goal attainment based on ESC/EAS guidelines. LDL-C goal attainment was achieved by only 23.4% of patients in the France cohort, compared to 31.6% in the rest of Europe cohort, indicating continued suboptimal lipid management in high cardiovascular risk patients in France.